-
1
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
3
-
-
50549123220
-
On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases
-
Beatson GT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-7.
-
(1896)
Lancet
, vol.2
, pp. 104-107
-
-
Beatson, G.T.1
-
4
-
-
77951614830
-
Monoclonal antibodies: versatile platforms for cancer immunotherapy
-
Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317-27.
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 317-327
-
-
Weiner, L.M.1
Surana, R.2
Wang, S.3
-
5
-
-
57749188299
-
Targeting cancer with small molecule kinase inhibitors
-
Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 28-39
-
-
Zhang, J.1
Yang, P.L.2
Gray, N.S.3
-
6
-
-
84867065769
-
Fc-fusion proteins: new developments and future perspectives
-
Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4: 1015-28.
-
(2012)
EMBO Mol Med
, vol.4
, pp. 1015-1028
-
-
Czajkowsky, D.M.1
Hu, J.2
Shao, Z.3
Pleass, R.J.4
-
7
-
-
84908460595
-
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin
-
Hoadley KA, Yau C, Wolf DM et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158: 929-44.
-
(2014)
Cell
, vol.158
, pp. 929-944
-
-
Hoadley, K.A.1
Yau, C.2
Wolf, D.M.3
-
8
-
-
84884762173
-
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
-
Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-90.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2783-2790
-
-
Dowsett, M.1
Sestak, I.2
Lopez-Knowles, E.3
-
9
-
-
0028806048
-
Quantitative monitoring of gene expression patterns with a complementary DNA microarray
-
Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
-
(1995)
Science
, vol.270
, pp. 467-470
-
-
Schena, M.1
Shalon, D.2
Davis, R.W.3
Brown, P.O.4
-
10
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sørlie, T.2
Eisen, M.B.3
-
11
-
-
18244409687
-
Gene expression profiling predicts clinical outcome of breast cancer
-
Van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
-
(2002)
Nature
, vol.415
, pp. 530-536
-
-
Van't Veer, L.J.1
Dai, H.2
van de Vijver, M.J.3
-
12
-
-
11144358111
-
Prognostically useful gene-expression profiles in acute myeloid leukemia
-
Valk PJM, Verhaak RGW, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-28.
-
(2004)
N Engl J Med
, vol.350
, pp. 1617-1628
-
-
Valk, P.J.M.1
Verhaak, R.G.W.2
Beijen, M.A.3
-
13
-
-
77954535843
-
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
-
Chibon F, Lagarde P, Salas S et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010; 16: 781-7.
-
(2010)
Nat Med
, vol.16
, pp. 781-787
-
-
Chibon, F.1
Lagarde, P.2
Salas, S.3
-
14
-
-
57349090407
-
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
-
Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
-
(2008)
N Engl J Med
, vol.359
, pp. 1995-2004
-
-
Hoshida, Y.1
Villanueva, A.2
Kobayashi, M.3
-
15
-
-
57649207038
-
Expression profiling with RNA from formalin-fixed, paraffin-embedded material
-
Oberli A, Popovici V, Delorenzi M et al. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med Genomics 2008; 1: 9.
-
(2008)
BMC Med Genomics
, vol.1
, pp. 9
-
-
Oberli, A.1
Popovici, V.2
Delorenzi, M.3
-
16
-
-
79951818662
-
Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue
-
Mittempergher L, de Ronde JJ, Nieuwland M et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 2011; 6: e17163.
-
(2011)
PLoS One
, vol.6
, pp. e17163
-
-
Mittempergher, L.1
de Ronde, J.J.2
Nieuwland, M.3
-
17
-
-
84876671873
-
Cancer gene expression signatures - the rise and fall?
-
Chibon F. Cancer gene expression signatures - the rise and fall? Eur J Cancer 2013; 49: 2000-9.
-
(2013)
Eur J Cancer
, vol.49
, pp. 2000-2009
-
-
Chibon, F.1
-
19
-
-
84899740340
-
DNA sequencing of cancer: what have we learned?
-
Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned? Annu Rev Med 2014; 65: 63-79.
-
(2014)
Annu Rev Med
, vol.65
, pp. 63-79
-
-
Chmielecki, J.1
Meyerson, M.2
-
20
-
-
53649106195
-
Next-generation DNA sequencing
-
Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-45.
-
(2008)
Nat Biotechnol
, vol.26
, pp. 1135-1145
-
-
Shendure, J.1
Ji, H.2
-
21
-
-
79953874259
-
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
Robert NJ, Diéras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-60.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1252-1260
-
-
Robert, N.J.1
Diéras, V.2
Glaspy, J.3
-
22
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
23
-
-
84894114159
-
A randomized trial of bevacizumab for newly diagnosed glioblastoma
-
Gilbert MR, Dignam JJ, Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708.
-
(2014)
N Engl J Med
, vol.370
, pp. 699-708
-
-
Gilbert, M.R.1
Dignam, J.J.2
Armstrong, T.S.3
-
24
-
-
84894194756
-
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
-
Chinot OL, Wick W, Mason W et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-22.
-
(2014)
N Engl J Med
, vol.370
, pp. 709-722
-
-
Chinot, O.L.1
Wick, W.2
Mason, W.3
-
25
-
-
84983118852
-
Scientific conclusions and grounds for refusal of the variation presented by the European Medicines Agency
-
European Medicines Agency. Scientific conclusions and grounds for refusal of the variation presented by the European Medicines Agency.
-
-
-
-
26
-
-
84864367909
-
Global cancer transitions according to the Human Development Index (2008-2030): a population-based study
-
Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012; 13: 790-801.
-
(2012)
Lancet Oncol
, vol.13
, pp. 790-801
-
-
Bray, F.1
Jemal, A.2
Grey, N.3
Ferlay, J.4
Forman, D.5
-
27
-
-
84918815964
-
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012
-
Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer 2015; 136: E359-86.
-
(2015)
Int J Cancer
, vol.136
, pp. E359-E386
-
-
Ferlay, J.1
Soerjomataram, I.2
Dikshit, R.3
-
28
-
-
33646568784
-
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world
-
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2137-2150
-
-
Kamangar, F.1
Dores, G.M.2
Anderson, W.F.3
-
29
-
-
80054914456
-
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
-
Forouzanfar MH, Foreman KJ, Delossantos AM et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378: 1461-84.
-
(2011)
Lancet
, vol.378
, pp. 1461-1484
-
-
Forouzanfar, M.H.1
Foreman, K.J.2
Delossantos, A.M.3
-
30
-
-
27244434470
-
Effect of screening and adjuvant therapy on mortality from breast cancer
-
Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-92.
-
(2005)
N Engl J Med
, vol.353
, pp. 1784-1792
-
-
Berry, D.A.1
Cronin, K.A.2
Plevritis, S.K.3
-
31
-
-
0003753478
-
SEER cancer statistics review, 1975-2005
-
Bethesda, MD, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
-
Reis L, Melbert D, Krapcho M et al. SEER cancer statistics review, 1975-2005. Natl Cancer Inst Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
-
Natl Cancer Inst
-
-
Reis, L.1
Melbert, D.2
Krapcho, M.3
-
32
-
-
34548232762
-
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data
-
Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-96.
-
(2007)
Lancet Oncol
, vol.8
, pp. 784-796
-
-
Verdecchia, A.1
Francisci, S.2
Brenner, H.3
-
33
-
-
82955237376
-
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
-
Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat 2011; 130: 553-60.
-
(2011)
Breast Cancer Res Treat
, vol.130
, pp. 553-560
-
-
Foukakis, T.1
Fornander, T.2
Lekberg, T.3
Hellborg, H.4
Adolfsson, J.5
Bergh, J.6
-
34
-
-
84983199361
-
Prognostic and predictive factors in early, non-metastatic breast cancer
-
Dizon Ed UpToDate Waltham, MA.
-
Foukakis T, Bergh J. Prognostic and predictive factors in early, non-metastatic breast cancer. Dizon Ed UpToDate Waltham, MA.
-
-
-
Foukakis, T.1
Bergh, J.2
-
35
-
-
0032896905
-
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
-
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1474-1481
-
-
Harvey, J.M.1
Clark, G.M.2
Osborne, C.K.3
Allred, D.C.4
-
36
-
-
0035865149
-
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer
-
Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-91.
-
(2001)
J Clin Oncol
, vol.19
, pp. 980-991
-
-
Ravdin, P.M.1
Siminoff, L.A.2
Davis, G.J.3
-
37
-
-
79960844327
-
Improved web-based calculators for predicting breast carcinoma outcomes
-
Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat 2011; 128: 827-35.
-
(2011)
Breast Cancer Res Treat
, vol.128
, pp. 827-835
-
-
Michaelson, J.S.1
Chen, L.L.2
Bush, D.3
Fong, A.4
Smith, B.5
Younger, J.6
-
38
-
-
0037417672
-
A web-based system for individualised survival estimation in breast cancer
-
Lundin J, Lundin M, Isola J, Joensuu H. A web-based system for individualised survival estimation in breast cancer. BMJ 2003; 326: 29.
-
(2003)
BMJ
, vol.326
, pp. 29
-
-
Lundin, J.1
Lundin, M.2
Isola, J.3
Joensuu, H.4
-
39
-
-
34248595234
-
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
-
De Azambuja E, Cardoso F, de Castro Jr G et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 2007; 96: 1504-13.
-
(2007)
Br J Cancer
, vol.96
, pp. 1504-1513
-
-
De Azambuja, E.1
Cardoso, F.2
de Castro, G.3
-
40
-
-
48849096940
-
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients
-
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast 2008; 17: 323-34.
-
(2008)
Breast
, vol.17
, pp. 323-334
-
-
Stuart-Harris, R.1
Caldas, C.2
Pinder, S.E.3
Pharoah, P.4
-
41
-
-
36849069347
-
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
-
Harris L, Fritsche H, Mennel R et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5287-5312
-
-
Harris, L.1
Fritsche, H.2
Mennel, R.3
-
42
-
-
84885366396
-
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi7-23.
-
(2013)
Ann Oncol
, vol.24
, pp. vi7-v23
-
-
Senkus, E.1
Kyriakides, S.2
Penault-Llorca, F.3
-
43
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
-
(2004)
N Engl J Med
, vol.351
, pp. 2817-2826
-
-
Paik, S.1
Shak, S.2
Tang, G.3
-
44
-
-
33744814477
-
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
-
Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3726-3734
-
-
Paik, S.1
Tang, G.2
Shak, S.3
-
45
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 10869-10874
-
-
Sørlie, T.1
Perou, C.M.2
Tibshirani, R.3
-
46
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1160-1167
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.U.3
-
47
-
-
13844310310
-
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
-
Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-9.
-
(2005)
Lancet
, vol.365
, pp. 671-679
-
-
Wang, Y.1
Klijn, J.G.2
Zhang, Y.3
-
48
-
-
2942578063
-
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
-
Ma X-J, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-16.
-
(2004)
Cancer Cell
, vol.5
, pp. 607-616
-
-
Ma, X.-J.1
Wang, Z.2
Ryan, P.D.3
-
49
-
-
80052845090
-
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
-
Filipits M, Rudas M, Jakesz R et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-20.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6012-6020
-
-
Filipits, M.1
Rudas, M.2
Jakesz, R.3
-
50
-
-
26444546442
-
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
-
Miller LD, Smeds J, George J et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005; 102: 13550-5.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 13550-13555
-
-
Miller, L.D.1
Smeds, J.2
George, J.3
-
51
-
-
33751261643
-
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
-
Ivshina AV, George J, Senko O et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006; 66: 10292-301.
-
(2006)
Cancer Res
, vol.66
, pp. 10292-10301
-
-
Ivshina, A.V.1
George, J.2
Senko, O.3
-
52
-
-
33144462268
-
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
-
Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-72.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 262-272
-
-
Sotiriou, C.1
Wirapati, P.2
Loi, S.3
-
53
-
-
84899475073
-
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients
-
Tobin NP, Lindström LS, Carlson JW, Bjöhle J, Bergh J, Wennmalm K. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients. Mol Oncol 2014; 8: 741-52.
-
(2014)
Mol Oncol
, vol.8
, pp. 741-752
-
-
Tobin, N.P.1
Lindström, L.S.2
Carlson, J.W.3
Bjöhle, J.4
Bergh, J.5
Wennmalm, K.6
-
54
-
-
34247145491
-
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
-
Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-46.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1239-1246
-
-
Loi, S.1
Haibe-Kains, B.2
Desmedt, C.3
-
55
-
-
66849140730
-
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
-
Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 736-750
-
-
Cheang, M.C.U.1
Chia, S.K.2
Voduc, D.3
-
56
-
-
84864085607
-
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression
-
Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-8.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2601-2608
-
-
Lindstrom, L.S.1
Karlsson, E.2
Wilking, U.M.3
-
57
-
-
84863116159
-
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors
-
Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2011; 30: 593-9.
-
(2011)
J Clin Oncol
, vol.30
, pp. 593-599
-
-
Niikura, N.1
Liu, J.2
Hayashi, N.3
-
58
-
-
78049459908
-
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
-
Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12: R92.
-
(2010)
Breast Cancer Res
, vol.12
, pp. R92
-
-
Thompson, A.M.1
Jordan, L.B.2
Quinlan, P.3
-
59
-
-
84922561724
-
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
-
Tobin NP, Harrell JC, Lövrot J et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol 2015; 26: 81-8.
-
(2015)
Ann Oncol
, vol.26
, pp. 81-88
-
-
Tobin, N.P.1
Harrell, J.C.2
Lövrot, J.3
-
60
-
-
85203363507
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
-
Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84.
-
(2011)
Lancet
, vol.378
, pp. 771-784
-
-
Davies, C.1
Godwin, J.2
Gray, R.3
-
61
-
-
78049505385
-
Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer
-
Howell A, Bergh J. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer. J Clin Oncol 2010; 28: 4548-50.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4548-4550
-
-
Howell, A.1
Bergh, J.2
-
62
-
-
75749092296
-
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
-
Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-18.
-
(2010)
J Clin Oncol
, vol.28
, pp. 509-518
-
-
Dowsett, M.1
Cuzick, J.2
Ingle, J.3
-
63
-
-
77649189240
-
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
-
Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009; (4): CD003370.
-
(2009)
Cochrane Database Syst Rev
, Issue.4
, pp. CD003370
-
-
Gibson, L.1
Lawrence, D.2
Dawson, C.3
Bliss, J.4
-
64
-
-
84864512253
-
Combination anastrozole and fulvestrant in metastatic breast cancer
-
Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-44.
-
(2012)
N Engl J Med
, vol.367
, pp. 435-444
-
-
Mehta, R.S.1
Barlow, W.E.2
Albain, K.S.3
-
65
-
-
84863892191
-
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer
-
Bergh J, Jönsson P-E, Lidbrink EK et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 30: 1919-25.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1919-1925
-
-
Bergh, J.1
Jönsson, P.-E.2
Lidbrink, E.K.3
-
66
-
-
84892648688
-
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
-
djt337
-
Leo AD, Jerusalem G, Petruzelka L et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106: djt337.
-
(2014)
J Natl Cancer Inst
, vol.106
-
-
Leo, A.D.1
Jerusalem, G.2
Petruzelka, L.3
-
67
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
68
-
-
84888391516
-
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
-
Toy W, Shen Y, Won H et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45: 1439-45.
-
(2013)
Nat Genet
, vol.45
, pp. 1439-1445
-
-
Toy, W.1
Shen, Y.2
Won, H.3
-
69
-
-
84888381937
-
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
-
Robinson DR, Wu Y-M, Vats P et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013; 45: 1446-51.
-
(2013)
Nat Genet
, vol.45
, pp. 1446-1451
-
-
Robinson, D.R.1
Wu, Y.-M.2
Vats, P.3
-
70
-
-
84922480878
-
Breast cancer during follow-up and progression - a population based cohort on new cancers and changed biology
-
Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J. Breast cancer during follow-up and progression - a population based cohort on new cancers and changed biology. Eur J Cancer 2014; 50: 2916-24.
-
(2014)
Eur J Cancer
, vol.50
, pp. 2916-2924
-
-
Karlsson, E.1
Appelgren, J.2
Solterbeck, A.3
Bergenheim, M.4
Alvariza, V.5
Bergh, J.6
-
71
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
72
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
73
-
-
84884418164
-
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
-
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013; 382: 1021-8.
-
(2013)
Lancet
, vol.382
, pp. 1021-1028
-
-
Goldhirsch, A.1
Gelber, R.D.2
Piccart-Gebhart, M.J.3
-
74
-
-
80052728749
-
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31
-
Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-73.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3366-3373
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
-
75
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
76
-
-
22344446208
-
Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
-
Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-74.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
77
-
-
84868520609
-
Trastuzumab emtansine for HER2-positive advanced breast cancer
-
Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91.
-
(2012)
N Engl J Med
, vol.367
, pp. 1783-1791
-
-
Verma, S.1
Miles, D.2
Gianni, L.3
-
78
-
-
84933556321
-
CEREBEL (EGF111438): a Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
-
Pivot X, Manikhas A, Zurawski B et al. CEREBEL (EGF111438): a Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015; 33: 1564-73.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1564-1573
-
-
Pivot, X.1
Manikhas, A.2
Zurawski, B.3
-
79
-
-
84866536687
-
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919
-
LBA671, ASCO Annual Meeting Abstracts. No 15_suppl (May 20 Supplement), 2012
-
Gelmon KA, Boyle F, Kaufman B et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012; ASCO Annual Meeting Abstracts. 30 No 15_suppl (May 20 Supplement), 2012: LBA671.
-
(2012)
J Clin Oncol
, vol.30
-
-
Gelmon, K.A.1
Boyle, F.2
Kaufman, B.3
-
80
-
-
84855297353
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
-
Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
-
(2012)
Lancet Oncol
, vol.13
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.-H.3
-
81
-
-
84908602324
-
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
-
De Azambuja E, Holmes AP, Piccart-Gebhart M et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014; 15: 1137-46.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1137-1146
-
-
De Azambuja, E.1
Holmes, A.P.2
Piccart-Gebhart, M.3
-
82
-
-
84923052492
-
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
-
Swain SM, Baselga J, Kim S-B et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-34.
-
(2015)
N Engl J Med
, vol.372
, pp. 724-734
-
-
Swain, S.M.1
Baselga, J.2
Kim, S.-B.3
-
83
-
-
84864066561
-
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study
-
Blackwell KL, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30: 2585-92.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2585-2592
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
-
84
-
-
84904188903
-
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
-
Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72.
-
(2014)
Lancet
, vol.384
, pp. 164-172
-
-
Cortazar, P.1
Zhang, L.2
Untch, M.3
-
85
-
-
84912074300
-
Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies
-
Berruti A, Amoroso V, Gallo F et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 2014; 32: 3883-92.
-
(2014)
J Clin Oncol
, vol.32
, pp. 3883-3892
-
-
Berruti, A.1
Amoroso, V.2
Gallo, F.3
-
86
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
-
Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.-J.1
Van Cutsem, E.2
Feyereislova, A.3
-
87
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-9.
-
(2012)
N Engl J Med
, vol.366
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
-
88
-
-
84983180707
-
Overall survival results from BOLERO-2
-
Present EBCC-9
-
Piccart M, Hortobagyi G, Campone M, Pritchard K, Noguchi S, Rugo H. Overall survival results from BOLERO-2. Present EBCC-9, 2014.
-
(2014)
-
-
Piccart, M.1
Hortobagyi, G.2
Campone, M.3
Pritchard, K.4
Noguchi, S.5
Rugo, H.6
-
90
-
-
84948711798
-
The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
-
SABCS, abstract S3-01].
-
Tutt A, Ellis P, Kilburn L et al. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). SABCS, 2014 [abstract S3-01].
-
(2014)
-
-
Tutt, A.1
Ellis, P.2
Kilburn, L.3
-
91
-
-
84924760015
-
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
-
Oza AM, Cibula D, Benzaquen AO et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16: 87-97.
-
(2015)
Lancet Oncol
, vol.16
, pp. 87-97
-
-
Oza, A.M.1
Cibula, D.2
Benzaquen, A.O.3
-
92
-
-
0028243879
-
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
-
Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-71.
-
(1994)
Nature
, vol.369
, pp. 669-671
-
-
Wang, T.C.1
Cardiff, R.D.2
Zukerberg, L.3
Lees, E.4
Arnold, A.5
Schmidt, E.V.6
-
93
-
-
0027280084
-
Expression and amplification of cyclin genes in human breast cancer
-
Buckley MF, Sweeney KJ, Hamilton JA et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127-33.
-
(1993)
Oncogene
, vol.8
, pp. 2127-2133
-
-
Buckley, M.F.1
Sweeney, K.J.2
Hamilton, J.A.3
-
94
-
-
84922369296
-
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
-
Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25-35.
-
(2015)
Lancet Oncol
, vol.16
, pp. 25-35
-
-
Finn, R.S.1
Crown, J.P.2
Lang, I.3
-
95
-
-
84885341769
-
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Labianca R, Nordlinger B, Beretta GD et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi64-72.
-
(2013)
Ann Oncol
, vol.24
, pp. vi64-vi72
-
-
Labianca, R.1
Nordlinger, B.2
Beretta, G.D.3
-
96
-
-
84908142852
-
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
-
Hong YS, Nam B-H, Kim K-P et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245-53.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1245-1253
-
-
Hong, Y.S.1
Nam, B.-H.2
Kim, K.-P.3
-
97
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2938-2947
-
-
De Gramont, A.1
Figer, A.2
Seymour, M.3
-
98
-
-
2142703727
-
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
-
Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1209-1214
-
-
Grothey, A.1
Sargent, D.2
Goldberg, R.M.3
Schmoll, H.-J.4
-
99
-
-
84903547973
-
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
-
Taieb J, Tabernero J, Mini E et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 862-73.
-
(2014)
Lancet Oncol
, vol.15
, pp. 862-873
-
-
Taieb, J.1
Tabernero, J.2
Mini, E.3
-
100
-
-
84859403854
-
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
-
Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-93.
-
(2012)
JAMA
, vol.307
, pp. 1383-1393
-
-
Alberts, S.R.1
Sargent, D.J.2
Nair, S.3
-
101
-
-
84870244259
-
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
-
De Gramont A, Van Cutsem E, Schmoll H-J et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-33.
-
(2012)
Lancet Oncol
, vol.13
, pp. 1225-1233
-
-
De Gramont, A.1
Van Cutsem, E.2
Schmoll, H.-J.3
-
102
-
-
79551521053
-
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
-
Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-6.
-
(2011)
J Clin Oncol
, vol.29
, pp. 11-16
-
-
Allegra, C.J.1
Yothers, G.2
O'Connell, M.J.3
-
103
-
-
84885090356
-
Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial
-
Uehara K, Hiramatsu K, Maeda A et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol 2013; 43: 964-71.
-
(2013)
Jpn J Clin Oncol
, vol.43
, pp. 964-971
-
-
Uehara, K.1
Hiramatsu, K.2
Maeda, A.3
-
104
-
-
84878979173
-
Predictive biomarkers for bevacizumab: are we there yet?
-
Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res 2013; 19: 2824-7.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2824-2827
-
-
Maru, D.1
Venook, A.P.2
Ellis, L.M.3
-
105
-
-
0035253739
-
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
-
Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
-
(2001)
J Clin Oncol
, vol.19
, pp. 843-850
-
-
Gordon, M.S.1
Margolin, K.2
Talpaz, M.3
-
106
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
107
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
-
108
-
-
84884700039
-
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
-
Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-85.
-
(2013)
Lancet Oncol
, vol.14
, pp. 1077-1085
-
-
Cunningham, D.1
Lang, I.2
Marcuello, E.3
-
109
-
-
77955497309
-
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
-
Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-8.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3191-3198
-
-
Tebbutt, N.C.1
Wilson, K.2
Gebski, V.J.3
-
110
-
-
84908139591
-
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
-
Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-18.
-
(2014)
N Engl J Med
, vol.371
, pp. 1609-1618
-
-
Loupakis, F.1
Cremolini, C.2
Masi, G.3
-
111
-
-
84868584808
-
Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM)
-
Pericay C, Folprecht G, Saunders M et al. Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 2012; 23 (abstract O-0024): iv5-18.
-
(2012)
Ann Oncol
, vol.23
, pp. iv5-i18
-
-
Pericay, C.1
Folprecht, G.2
Saunders, M.3
-
112
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-506.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
-
113
-
-
33746889808
-
A comprehensive pathway map of epidermal growth factor receptor signaling
-
0010 (Epub 2005 May 25).
-
Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 25.0010 (Epub 2005 May 25).
-
(2005)
Mol Syst Biol
, vol.1
, pp. 25
-
-
Oda, K.1
Matsuoka, Y.2
Funahashi, A.3
Kitano, H.4
-
114
-
-
33745828702
-
EGF-ERBB signalling: towards the systems level
-
Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 505-516
-
-
Citri, A.1
Yarden, Y.2
-
115
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
116
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
-
Douillard J-Y, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.-Y.1
Siena, S.2
Cassidy, J.3
-
117
-
-
38649099966
-
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
-
Lièvre A, Bachet J-B, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 374-379
-
-
Lièvre, A.1
Bachet, J.-B.2
Boige, V.3
-
118
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
119
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard J-Y, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.-Y.1
Oliner, K.S.2
Siena, S.3
-
120
-
-
84925324704
-
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
-
Van Cutsem E, Lenz H-J, Köhne C-H et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700.
-
(2015)
J Clin Oncol
, vol.33
, pp. 692-700
-
-
Van Cutsem, E.1
Lenz, H.-J.2
Köhne, C.-H.3
-
121
-
-
84907023716
-
Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab
-
Bokemeyer C, Kohne C-H, Ciardiello F et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 2014; 32: 5s.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Bokemeyer, C.1
Kohne, C.-H.2
Ciardiello, F.3
-
122
-
-
84911474269
-
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
iii1-iii9.
-
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, On behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii1-9.
-
(2014)
Ann Oncol
, vol.25
-
-
Van Cutsem, E.1
Cervantes, A.2
Nordlinger, B.3
Arnold, D.4
-
123
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Köhne C-H, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Köhne, C.-H.2
Hitre, E.3
-
124
-
-
78149239651
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-13.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4706-4713
-
-
Peeters, M.1
Price, T.J.2
Cervantes, A.3
-
125
-
-
44249111440
-
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
-
Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2311-2319
-
-
Sobrero, A.F.1
Maurel, J.2
Fehrenbacher, L.3
-
126
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
-
Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-75.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
von Weikersthal, L.F.2
Decker, T.3
-
127
-
-
84907027361
-
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
-
Venook AP, Niedzwiecki D, Lenz H-J et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014; 32: 5s.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Venook, A.P.1
Niedzwiecki, D.2
Lenz, H.-J.3
-
128
-
-
79954499886
-
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
-
Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-55.
-
(2011)
Int J Cancer
, vol.129
, pp. 245-255
-
-
Wilhelm, S.M.1
Dumas, J.2
Adnane, L.3
-
129
-
-
85084273846
-
O-0023concur: a randomized, double-blind, placebo-controlled Phase 3 study of regorafenib monotherapy in asian patients with previously treated metastatic colorectal cancer (mcrc)
-
Li J, Qin S, Yau T et al. O-0023concur: a randomized, double-blind, placebo-controlled Phase 3 study of regorafenib monotherapy in asian patients with previously treated metastatic colorectal cancer (mcrc). Ann Oncol 2014; 25: ii114-5.
-
(2014)
Ann Oncol
, vol.25
, pp. ii114-ii115
-
-
Li, J.1
Qin, S.2
Yau, T.3
-
130
-
-
84872921660
-
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
-
Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
-
(2013)
Lancet
, vol.381
, pp. 303-312
-
-
Grothey, A.1
Van Cutsem, E.2
Sobrero, A.3
-
131
-
-
84923202077
-
Colorectal cancer in 2014: progress in defining first-line and maintenance therapies
-
Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol 2015; 12: 73-4.
-
(2015)
Nat Rev Clin Oncol
, vol.12
, pp. 73-74
-
-
Hubbard, J.M.1
Grothey, A.2
-
132
-
-
84888021467
-
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis
-
Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2013; 15: e711-8.
-
(2013)
Colorectal Dis
, vol.15
, pp. e711-e718
-
-
Clancy, C.1
Burke, J.P.2
Kalady, M.F.3
Coffey, J.C.4
-
133
-
-
84867298938
-
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis
-
Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012; 7: e47054.
-
(2012)
PLoS One
, vol.7
, pp. e47054
-
-
Safaee Ardekani, G.1
Jafarnejad, S.M.2
Tan, L.3
Saeedi, A.4
Li, G.5
-
134
-
-
84879786289
-
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
-
Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-59.
-
(2013)
Lancet Oncol
, vol.14
, pp. 749-759
-
-
Seymour, M.T.1
Brown, S.R.2
Middleton, G.3
-
135
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
136
-
-
78649723255
-
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
-
Kopetz S, Desai J, Chan E et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28: 15s.
-
(2010)
J Clin Oncol
, vol.28
, pp. 15s
-
-
Kopetz, S.1
Desai, J.2
Chan, E.3
-
137
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
-
Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-901.
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
138
-
-
84856549042
-
Genome-scale analysis of aberrant DNA methylation in colorectal cancer
-
Hinoue T, Weisenberger DJ, Lange CPE et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-82.
-
(2012)
Genome Res
, vol.22
, pp. 271-282
-
-
Hinoue, T.1
Weisenberger, D.J.2
Lange, C.P.E.3
-
139
-
-
67649506174
-
Genetic prognostic and predictive markers in colorectal cancer
-
Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-99.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 489-499
-
-
Walther, A.1
Johnstone, E.2
Swanton, C.3
Midgley, R.4
Tomlinson, I.5
Kerr, D.6
-
140
-
-
84877600884
-
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
-
De Sousa E, Melo F, Wang X, Jansen M et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-8.
-
(2013)
Nat Med
, vol.19
, pp. 614-618
-
-
De Sousa, E.1
Melo, F.2
Wang, X.3
Jansen, M.4
-
141
-
-
84877619075
-
A colorectal cancer classification system that associates cellular phenotype and responses to therapy
-
Sadanandam A, Lyssiotis CA, Homicsko K et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-25.
-
(2013)
Nat Med
, vol.19
, pp. 619-625
-
-
Sadanandam, A.1
Lyssiotis, C.A.2
Homicsko, K.3
-
142
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
143
-
-
84878302099
-
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value
-
Marisa L, de Reyniès A, Duval A et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013; 10: e1001453.
-
(2013)
PLoS Med
, vol.10
, pp. e1001453
-
-
Marisa, L.1
de Reyniès, A.2
Duval, A.3
-
144
-
-
84923352670
-
Genomic landscape of metastatic colorectal cancer
-
Haan JC, Labots M, Rausch C et al. Genomic landscape of metastatic colorectal cancer. Nat Commun 2014; 5: 5457.
-
(2014)
Nat Commun
, vol.5
, pp. 5457
-
-
Haan, J.C.1
Labots, M.2
Rausch, C.3
-
145
-
-
84920944831
-
Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes
-
Linnekamp JF, Wang X, Medema JP, Vermeulen L. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res 2015; 75: 245-9.
-
(2015)
Cancer Res
, vol.75
, pp. 245-249
-
-
Linnekamp, J.F.1
Wang, X.2
Medema, J.P.3
Vermeulen, L.4
-
146
-
-
84896856425
-
Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications
-
Sadanandam A, Wang X, de Sousa E, Melo F et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 2014; 13: 353-7.
-
(2014)
Cell Cycle
, vol.13
, pp. 353-357
-
-
Sadanandam, A.1
Wang, X.2
de Sousa, E.3
Melo, F.4
-
147
-
-
84911493241
-
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
iii27-iii39.
-
Reck M, Popat S, Reinmuth N et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii27-39.
-
(2014)
Ann Oncol
, vol.25
-
-
Reck, M.1
Popat, S.2
Reinmuth, N.3
-
148
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
149
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.-L.2
Chen, G.3
-
150
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
151
-
-
84983212214
-
First-line erlotinib versus cisplatin/gemcitabine (gp) in patients with advanced egfr mutation-positive nonsmall-cell lung cancer (nsclc): interim analyses from the phase 3, open-label, ENSURE study
-
World Conf Lung Cancer, poster P1.11-021].
-
Wu Y-L. First-line erlotinib versus cisplatin/gemcitabine (gp) in patients with advanced egfr mutation-positive nonsmall-cell lung cancer (nsclc): interim analyses from the phase 3, open-label, ENSURE study. World Conf Lung Cancer, 2013, [poster P1.11-021].
-
(2013)
-
-
Wu, Y.-L.1
-
152
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.-L.2
Thongprasert, S.3
-
153
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
154
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
-
Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
-
(2010)
Lancet Oncol
, vol.11
, pp. 121-128
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
155
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
Sequist LV, Yang JC-H, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3327-3334
-
-
Sequist, L.V.1
Yang, J.-H.2
Yamamoto, N.3
-
156
-
-
84892997539
-
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
-
Wu Y-L, Zhou C, Hu C-P et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-22.
-
(2014)
Lancet Oncol
, vol.15
, pp. 213-222
-
-
Wu, Y.-L.1
Zhou, C.2
Hu, C.-P.3
-
157
-
-
84921892043
-
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
-
Yang JC-H, Wu Y-L, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-51.
-
(2015)
Lancet Oncol
, vol.16
, pp. 141-151
-
-
Yang, J.-H.1
Wu, Y.-L.2
Schuler, M.3
-
158
-
-
84908127948
-
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
-
Seto T, Kato T, Nishio M et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-44.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1236-1244
-
-
Seto, T.1
Kato, T.2
Nishio, M.3
-
159
-
-
84927061520
-
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer
-
Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 2015; 121: E1-6.
-
(2015)
Cancer
, vol.121
, pp. E1-E6
-
-
Steuer, C.E.1
Khuri, F.R.2
Ramalingam, S.S.3
-
160
-
-
84867395679
-
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
-
Thunnissen E, Bubendorf L, Dietel M et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012; 461: 245-57.
-
(2012)
Virchows Arch
, vol.461
, pp. 245-257
-
-
Thunnissen, E.1
Bubendorf, L.2
Dietel, M.3
-
161
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim D-W, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-94.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.-W.2
Nakagawa, K.3
-
162
-
-
84918804764
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
-
Solomon BJ, Mok T, Kim D-W et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-77.
-
(2014)
N Engl J Med
, vol.371
, pp. 2167-2177
-
-
Solomon, B.J.1
Mok, T.2
Kim, D.-W.3
-
163
-
-
84905366894
-
Acquired resistance to TKIs in solid tumours: learning from lung cancer
-
Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11: 473-81.
-
(2014)
Nat Rev Clin Oncol
, vol.11
, pp. 473-481
-
-
Camidge, D.R.1
Pao, W.2
Sequist, L.V.3
-
164
-
-
84903482432
-
Ceritinib in ALK-rearranged non-small-cell lung cancer
-
Shaw AT, Kim D-W, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189-97.
-
(2014)
N Engl J Med
, vol.370
, pp. 1189-1197
-
-
Shaw, A.T.1
Kim, D.-W.2
Mehra, R.3
-
165
-
-
84911372597
-
Crizotinib in ROS1-rearranged non-small-cell lung cancer
-
Shaw AT, Ou S-HI, Bang Y-J et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-71.
-
(2014)
N Engl J Med
, vol.371
, pp. 1963-1971
-
-
Shaw, A.T.1
Ou, S.-H.2
Bang, Y.-J.3
-
166
-
-
80053014471
-
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations
-
Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011; 29: 3574-9.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3574-3579
-
-
Marchetti, A.1
Felicioni, L.2
Malatesta, S.3
-
167
-
-
84926028427
-
Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928)
-
Planchard D, Kim T, Mazières J et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928). Ann Oncol 2014; 25 [abstract LBA38_PR]: v1-41.
-
(2014)
Ann Oncol
, vol.25
, pp. v1-41
-
-
Planchard, D.1
Kim, T.2
Mazières, J.3
-
168
-
-
84870748688
-
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer
-
Wang R, Hu H, Pan Y et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012; 30: 4352-9.
-
(2012)
J Clin Oncol
, vol.30
, pp. 4352-4359
-
-
Wang, R.1
Hu, H.2
Pan, Y.3
-
169
-
-
84876383602
-
A patient with lung adenocarcinoma and RET fusion treated with vandetanib
-
Gautschi O, Zander T, Keller FA et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013; 8: e43-4.
-
(2013)
J Thorac Oncol
, vol.8
, pp. e43-e44
-
-
Gautschi, O.1
Zander, T.2
Keller, F.A.3
-
170
-
-
84975797039
-
Nivolumab approved for lung cancer
-
Nivolumab approved for lung cancer. Cancer Discov 2015; 5: OF1.
-
(2015)
Cancer Discov
, vol.5
, pp. OF1
-
-
-
171
-
-
84859438079
-
Hurdles in anticancer drug development from a regulatory perspective
-
Jonsson B, Bergh J. Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol 2012; 9: 236-43.
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 236-243
-
-
Jonsson, B.1
Bergh, J.2
-
172
-
-
84873186179
-
Deciphering signatures of mutational processes operative in human cancer
-
Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013; 3: 246-59.
-
(2013)
Cell Rep
, vol.3
, pp. 246-259
-
-
Alexandrov, L.B.1
Nik-Zainal, S.2
Wedge, D.C.3
Campbell, P.J.4
Stratton, M.R.5
-
173
-
-
84861541343
-
Mutational processes molding the genomes of 21 breast cancers
-
Nik-Zainal S, Alexandrov LB, Wedge DC et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-93.
-
(2012)
Cell
, vol.149
, pp. 979-993
-
-
Nik-Zainal, S.1
Alexandrov, L.B.2
Wedge, D.C.3
-
174
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
-
(2012)
N Engl J Med
, vol.366
, pp. 883-892
-
-
Gerlinger, M.1
Rowan, A.J.2
Horswell, S.3
-
175
-
-
58149354867
-
Quo vadis with targeted drugs in the 21st century?
-
Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol 2009; 27: 2-5.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2-5
-
-
Bergh, J.1
-
176
-
-
84862584058
-
Whole-genome analysis informs breast cancer response to aromatase inhibition
-
Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-60.
-
(2012)
Nature
, vol.486
, pp. 353-360
-
-
Ellis, M.J.1
Ding, L.2
Shen, D.3
|